Actos (pioglitazone), manufactured by Takeda Pharmaceuticals, is an oral diabetes medicine that helps control blood sugar levels for people with Type 2 diabetes. It is not prescribed for patients with Type 1 diabetes.
The long-term use of Actos is linked to a number of serious health complications. One of the most alarming and deadly side effects is a significantly higher risk of bladder cancer. One study found that patients taking high doses of Actos for at least one year were 40% more likely to develop bladder cancer over time. The drug has already been pulled from the market in Germany, France and India.